Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Cerus Corporation, a leading biotechnology firm headquartered in the United States, has been at the forefront of blood safety and transfusion medicine since its founding in 1991. With a strong operational presence across North America and Europe, Cerus is dedicated to developing innovative solutions that enhance the safety of blood products.
The company’s flagship product, the INTERCEPT Blood System, utilises advanced pathogen inactivation technology, setting it apart in the industry. This system significantly reduces the risk of transfusion-transmitted infections, making it a vital tool for healthcare providers. Cerus has achieved notable milestones, including regulatory approvals and partnerships that underscore its commitment to improving patient outcomes. As a pioneer in blood safety, Cerus Corporation continues to solidify its market position through ongoing research and development, ensuring the highest standards in transfusion practices.
-13 vs industry average
Cerus Corporation’s score of 29 is lower than 47% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2022, Cerus Corporation reported total carbon emissions of approximately 30.5 million kg CO2e. This figure includes Scope 1 emissions of about 223,000 kg CO2e, Scope 2 emissions of approximately 473,000 kg CO2e, and a significant contribution from Scope 3 emissions, which totalled around 29.8 million kg CO2e. The Scope 3 emissions breakdown reveals major sources, including purchased goods and services (approximately 22 million kg CO2e) and business travel (about 1.2 million kg CO2e).
Cerus is committed to ambitious climate action, aiming to reduce its operational emissions to near zero by the middle of this decade. This commitment applies to both Scope 1 and Scope 2 emissions, with a target timeframe set from 2023 to 2025. The company is actively working towards these reduction initiatives as part of its sustainability strategy.
As of now, there are no emissions data cascaded from a parent or related organization, indicating that Cerus Corporation is independently reporting its emissions and climate commitments.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more